Reported Earlier, Estrella’s EB103 Dosed Twice Three Weeks Apart In First Dose-Expansion Patient At Recommended Phase II Dose, No Treatment-Related SAEs; Dose-Escalation Delivered 100% Month 1 Complete Response In High-Dose Cohort

Estrella's EB103 has been administered to the first patient in the dose-expansion phase, with two infusions given three weeks apart at the recommended Phase II dose. Notably, there were no treatment-related serious adverse events reported during the first month of follow-up. Additionally, the dose-escalation phase achieved a 100% complete response rate in the high-dose cohort for the first month.